The Zhitong Finance App learned that Citibank released a research report saying that Cinda Biotech (01801) announced that product revenue for the first half of 2026 exceeded 8.2 billion yuan, an increase of more than 55% over the previous year. Among them, product revenue for the second quarter exceeded 4.3 billion yuan, an increase of about 60% over the previous year, and the performance was superior to market expectations. The growth momentum comes from the “dual engine” strategy. The comprehensive product line has maintained strong growth. The core products Xinermei (Maxidopeptide Injection), Cinpirac (Tolexizumab Injection), and Cinbimin (Tetuumab N01 Injection) performed well and have become an important driving force for revenue growth. In the field of oncology, the market penetration rate of the five new tyrosine kinase inhibitors included in the national health insurance catalogue continues to increase. At the same time, the company and Eli Lilly agreed to successfully expand into the field of breast cancer treatment. Citi believes that Cinda Biotech is one of the preferred stocks in China's biotech sector and reaffirms its “buy” rating, with a target price of HK$115.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.